Form 8-K - Current report:
SEC Accession No. 0001731122-24-002063
Filing Date
2024-12-30
Accepted
2024-12-30 16:05:59
Documents
15
Period of Report
2024-12-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e6244_8-k.htm   iXBRL 8-K 29620
2 EXHIBIT 10.1 e6244_ex10-1.htm EX-10.1 14175
3 EXHIBIT 10.2 e6244_ex10-2.htm EX-10.2 11396
  Complete submission text file 0001731122-24-002063.txt   239075

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE vrpx-20241230.xsd EX-101.SCH 3027
5 XBRL LABEL FILE vrpx-20241230_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE vrpx-20241230_pre.xml EX-101.PRE 24173
17 EXTRACTED XBRL INSTANCE DOCUMENT e6244_8-k_htm.xml XML 3810
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

EIN.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 241589789
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)